Skip to content

Dry Eye in Upper Eyelid Surgery: Muscle Versus Fat Removal

Effects of Orbicularis Oculi and Fat Excision on Dry Eye in Upper Blepharoplasty: A Comparative Evaluation

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06985264
Enrollment
142
Registered
2025-05-22
Start date
2025-05-01
Completion date
2025-12-30
Last updated
2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Disorders

Brief summary

The aim of this study is to compare the effects of two different surgical techniques (Orbicularis Oculi excision and Orbicularis Oculi + Fat excision) applied in upper blepharoplasty surgery on dry eye and to evaluate the effects of these techniques on ocular surface health. 142 patients (71 patients in each group) who met the inclusion and exclusion criteria between 01.05.2025 and 31.12.2025 in Mersin City Education and Research Hospital Eye Diseases Clinic will be included in this study. This study is a prospective, survey study and aims to evaluate the effects of two different surgical techniques (Orbicularis Oculi excision only and Orbicularis Oculi + Fat excision) applied in upper blepharoplasty surgery on postoperative dry eye symptoms. The study will be conducted on patients who are currently scheduled for upper blepharoplasty surgery and no additional surgical procedures or interventions will be applied to the patients. Data collection will be done by a survey study and retrospective recording of routine clinical examinations. The collected data will be used to analyze the differences in dry eye parameters between the two surgical techniques. OSDI scores, BUT times, Oxford staining degrees, Schirmer test results and visual acuity values will be compared at pre- and postoperative time points. Differences between groups will be analyzed by one-tailed independent samples t-test and p<0.05 will be considered significant. These analyses will be performed to determine the effect of surgical techniques on dry eye symptoms.

Interventions

PROCEDUREUpper Eyelid Blepharoplasty surgery

Orbicularis oculi excision

Sponsors

Mersin Training and Research Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients who are currently undergoing Upper Eyelid Blepharoplasty 2. Patients between the ages of 18-80 3. Patients with a 6-month postoperative follow-up 4. Patients without a preoperative dry eye diagnosis 5. Patients who have not had previous eyelid surgery 6. Those who signed the Informed Consent Form/Written Consent Form 7. Patients with complete treatment and follow-up files

Exclusion criteria

1. Being under 18 and over 80 2. Having a history of previous eyelid surgery 3. Diabetics 4. Having diseases that cause dry eyes such as Sjögren, Systemic Lupus Erythematosus 5. Having dry eye disease before surgery

Design outcomes

Primary

MeasureTime frameDescription
Ocular Surface Disease Index (OSDI)Preoperative, postoperative 1st month, 3rd month and 6th month Ocular Surface Disease Index (OSDI) score survey will be conducted.The OSDI, which was created by the Outcomes Research Group at Allergan Inc in order to quickly assess the symptoms of ocular irritation in dry eye disease and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to none of the time and 4 corresponding to all of the time. A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026